ZAMBELLI, STEFANIA
 Distribuzione geografica
Continente #
AS - Asia 127
EU - Europa 119
NA - Nord America 114
SA - Sud America 15
Totale 375
Nazione #
US - Stati Uniti d'America 110
IT - Italia 75
CN - Cina 46
SG - Singapore 46
HK - Hong Kong 16
BR - Brasile 12
DE - Germania 10
GB - Regno Unito 10
VN - Vietnam 10
FI - Finlandia 7
NL - Olanda 5
SE - Svezia 4
CA - Canada 3
PL - Polonia 3
BD - Bangladesh 2
IN - India 2
RU - Federazione Russa 2
AR - Argentina 1
AT - Austria 1
FR - Francia 1
GY - Guiana 1
JO - Giordania 1
JP - Giappone 1
KR - Corea 1
LK - Sri Lanka 1
LT - Lituania 1
MX - Messico 1
PY - Paraguay 1
UZ - Uzbekistan 1
Totale 375
Città #
Singapore 24
Hong Kong 16
Ashburn 15
Milan 14
Shanghai 13
Boardman 8
Dallas 8
New York 8
Beijing 7
Hefei 6
Los Angeles 6
Ho Chi Minh City 5
Poplar 5
Denver 4
Lappeenranta 4
Cesano Boscone 3
Cornaredo 3
Costa de' Nobili 3
Helsinki 3
Nuremberg 3
Orem 3
Santa Clara 3
Warsaw 3
Atlanta 2
Bari 2
Cagliari 2
Chennai 2
Falkenstein 2
Fucecchio 2
Guangzhou 2
Hanoi 2
Livorno 2
Manchester 2
Naples 2
Perego 2
Phoenix 2
Pisa 2
Rome 2
Stezzano 2
Toronto 2
Amman 1
Amsterdam 1
Annapolis 1
Arezzo 1
Asunción 1
Bandaragama 1
Bologna 1
Boston 1
Changsha 1
City of London 1
Clarksburg 1
Cleveland 1
Clorinda 1
Council Bluffs 1
Curitiba 1
Dhaka 1
Esperança 1
Extrema 1
Ferraz de Vasconcelos 1
Figino 1
Georgetown 1
Jacksonville 1
Jiaxing 1
La Spezia 1
Lanham 1
Lanzhou 1
Lawrence 1
London 1
Messina 1
Moscow 1
Motta Sant'Anastasia 1
Nova Hartz 1
Ottawa 1
Palosco 1
Parnaíba 1
Pittsburgh 1
Princeton 1
Querétaro 1
Quận Bốn 1
Rimini 1
San Francisco 1
Shiremoor 1
Stockholm 1
São Carlos 1
São José dos Campos 1
São Paulo 1
Tashkent 1
Thái Nguyên 1
Tianjin 1
Tokyo 1
Uberlândia 1
Vargem Grande Paulista 1
Vilnius 1
Vĩnh Long 1
Wolfhagen 1
Yonkers 1
Totale 257
Nome #
Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice 105
Spatial predictors of immunotherapy response in triple-negative breast cancer 69
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study 62
Dermatological and Dermoscopic Baselines in BRCA Mutation Carriers 58
Modulation of the estrogen/erbB2 receptors crosstalk by CDK4/6 inhibition triggers sustained senescence in estrogen receptor and erbB2 positive breast cancer 56
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer 43
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer 2
Totale 395
Categoria #
all - tutte 2.071
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.071


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222 0 0 0 0 0 0 0 0 1 1 0 0
2022/20238 2 2 0 0 0 0 0 1 0 0 0 3
2023/202425 0 0 3 3 1 0 0 1 0 2 4 11
2024/2025168 21 11 4 11 19 17 20 31 7 4 7 16
2025/2026192 27 22 9 63 61 10 0 0 0 0 0 0
Totale 395